Liminatus Pharma, Inc. Class A Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.0M
- Price
- $3.70
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.27%
- Volume
- 12.5K
About
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Quick stats
Shares outstanding1.3M
Computed float669.8K
Float / shares49.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001971387
Websitehttps://liminatuspharma.com
AI Summary
AI-generated1/8
minorbullishregulatory
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Liminatus Pharma received notice from Nasdaq that it has regained compliance with the minimum bid price rule, and the matter is now closed.
The stock closed above $1.00 for 13 consecutive trading days from August 21 to September 9, 2026, following a 1-for-50 reverse split effected August 20. The company had been non-compliant since a January notice and was transferred to the Nasdaq Capital Market after a hearing.
While the delisting overhang is resolved, compliance was achieved via reverse split rather than sustained organic price appreciation — a lingering signal on the equity's standing.
Red flags
- compliance regained via 1-for-50 reverse split, not organic price recovery
- transferred from Nasdaq Global Market to Capital Market after hearings panel review